Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC assesses industry submission to NICE on new drug for ovarian cancer

Published: 17 October 2012
Ovarian cancer

SHTAC is assessing the clinical-effectiveness and cost-effectiveness of bevacizumab in combination with paclitaxel and carboplatin for ovarian cancer for the National Institute for Health and Clinical Excellence (NICE) appraisal process.

SHTAC is preparing an evidence review for the National Institute for Health and Clinical Excellence (NICE) to inform their single technology appraisal of bevacizumab for ovarian cancer. Three quarters of women who are diagnosed with ovarian cancer already have advanced disease, as there are often no symptoms in the early stages. Bevacizumab, which is licenced for first-line treatment of advanced ovarian cancer, aims to stop tumour growth. NICE is expected to issue guidance to the health service in England and Wales on bevacizumab in combination with paclitaxel and carboplatin in April 2013.

For details of SHTAC’s previous research on cancer please visit our Research page.

Privacy Settings